Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
HUMAN BioPlazma Kft. is part of Kedrion Biopharma, an international company specializing in the collection and fractionation of blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies.
Kedrion was established in Italy in 2001, but the roots of the companies from which it was born stretch back several decades in the production of blood and plasma derived products. A primarily family-owned business, it places a high value on the welfare of those who benefit from its products and also on the people and communities where it operates. HUMAN BioPlazma became part of Kedrion in 2008, but its own roots extend back to 1922 when its predecessor, the Phylaxia Vaccine Manufacturing company founded its Human Department in Budapest.
HUMAN BioPlazma collects plasma in its own plasma collection centers applying apheresis technology, and also receives plasma for further processing deriving from the excess amounts of whole blood donations, which are not required for transfusiology purposes as the partner of the Hungarian National Blood Transfusion Service.
We have been well-matched to join Kedrion, sharing its commitments and values of quality products, community values and a highly professional workforce.
Contact
H-2100 Gödöllő
Táncsics M. út 80
Hungary
Tel: +36 28 53 22 00
Fax: +36 28 53 22 01
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here
